Multiple use of the AN 69 membrane in hemodiafiltration: preliminary clinical experience.
Explore the source record for details and available documents.
Acrylic Resins↗
Biomedical subjects
Q V Nguyen
Publications and source records attributed to Q V Nguyen.
Immune response to intermediate filament-associated, Epstein-Barr virus-induced early antigen.
A murine monoclonal antibody (MAb) (15TD3) was found to recognize a unique filamentous structure in Epstein-Barr virus (EBV)-producing lymphoblastoid cell lines. By immunofluorescent morphology, in comparison with a control MAb to vimentin, the 15TD3 filamentous structure was judged to be associated with intermediate filaments of the cytoskeleton. Expression of the 15TD3 antigen and vimentin was induced simultaneously in some EBV genome-positive cell lines either by EBV superinfection or by 12-0-tetradecanoyl-1-phorbol-13-acetate (TPA) and n-butyrate treatment. The 15TD3 antigen was considered to be a restricted component of the EBV-induced early antigen (EA) complex. The 15TD3 antigen was expressed only in EBV genome-activated cells after either spontaneous EBV genome activation, EBV superinfection, or TPA and n-butyrate treatment. The expression of 15TD3 antigen paralleled the induction of EA in several models of induction of EBV antigens, and was detected only in EA+ cells which were stained with anti-EA+ human sera. The reactivity of 15TD3 MAb was blocked with anti-EA+ human serum, but not with anti-EA- serum. The synthesis of 15TD3 antigen was not inhibited with phosphonoacetic acid, was resistant to acetone fixation, and was sensitive to ethanol (or methanol) fixation. Human lymphoblastoid cells from patients with acute infectious mononucleosis were cloned for the production of antibodies which detected EBV-specific or -nonspecific epitopes on filamentous structures. Two human MAb were defined by two-color immunofluorescence to react to the 15TD3 determinants on intermediate filaments of EBV+ cells. This study supports the following views: that EBV genome activation induces a structure associated with intermediate filaments, and that antibodies against both the EBV-specific, intermediate filament-associated epitope and native intermediate filament epitopes are produced by some EBV-transformed lymphoblastoid cell lines from patients with infectious mononucleosis.
Antibodies, Monoclonal↗
Hemodiafiltration using dialysate as substitution fluid.
To reduce the cost of hemodiafiltration (HDF), a standard hemodialysis machine was modified to permit in-line production of substitution fluid from bicarbonate dialysate. The authors' present data showing that this procedure was made bacteriologically safe; was simple to use, and offered a cheap approach to perform high-flux HDF using a hemodifilter of relatively small membrane surface area.
Bicarbonates↗
Epstein-Barr virus-specific cytoskeletal early antigen in EBV-transformed cell lines.
An Epstein-Barr virus (EBV)-specific determinant of early antigen (EA) character was found to be associated with intermediate filaments of EBV genome-activated cells. This determinant was defined with a murine monoclonal antibody (MAb) and with human MAb derived from lymphoblastoid cell lines of patients with acute infectious mononucleosis (IM). Such patients' antibodies either recognized intermediate filament determinants in general, or were restricted to the intermediate filament determinant of EBV genome-activated cells, as also recognized with the 1B6 murine MAb. The 1B6 determinant was a component of EA as defined by phosphonoacetate-resistance, methanol-sensitivity, and various co-staining and antibody-blocking experiments. While anti-intermediate filament antibodies have been reported after various viral illnesses, the 1B6 and some patients' antibodies recognize an EBV-specific determinant which might function in the lytic cycle of these cells.
Antibodies, Monoclonal↗
A bedside micromethod for the determination of total carbon dioxide in biological fluids.
The quality control of bicarbonate hemodialysis requires the determination of TCO2, either in blood or in dialysate. The use of the M + D TCO2 kit, a bedside micromethod, gave the authors an economical and reliable solution to this problem.
Body Fluids↗
[Plasmid vectors with a semi-synthetic beta-galactosidase gene of E. coli].
A partial synthesis of a structural gene for beta-galactosidase and construction of a series of pLZ plasmids for quantitative study of E. coli promoters are reported. The gene was assembled of two short synthetic DNAs and of a 3000 bp long EcoRI fragment (comprising the lacZ sequence 16-3013) isolated from plasmid p198/1 of B. Gronenborn. Among the plasmids constructed, pLZ4 is a promoter-probe vector that contains the semi-synthetic gene fused with a synthetic Shine-Dalgarno sequence and preceded by unique EcoRI and KpnI cleavage sites. On cloning a promoter into these sites, its signal strength in vivo could easily be measured by assaying beta-galactosidase activity. The use of pLZ4 vector was demonstrated by quantifying the effect of T7 early promoters A1 and A2, the latter being found 4,5 times more active under the conditions employed.
Base Sequence↗
Reuse of "highly permeable" dialyzers with peroxyacetic acid as sole cleansing and disinfecting agent.
In the past few years, dialyzer reuse has gained increased clinical acceptance. This has been due both to the availability of automated reconditioning machines and powerful chemical cleaning and disinfecting agents. In this study the authors evaluated the effectiveness of a newly available peroxyacetic acid solution (PAS) (Dialox) as the dual cleaning and disinfecting agent in the reuse of highly permeable dialyzers. An in vivo study was conducted with ten patients already involved in our center's reuse program using the Renatron reprocessing machine and PAS at various dilutions. One hundred forty dialyzers of three different brands and membrane types (HF80 used for hemodiafiltration [HDF], Filtral 16 used for hemodialysis [HD], and FH88 used for hemofiltration [HF]) were employed for a total of 1182 treatments, giving an average 8.4 uses per module. Significantly more uses were obtained with the HF80 and Filtral 16 dialyzers (9.7 and 9.4, respectively) than for the FH88 modules used by the HF patients (6.7 uses per module). Compromised cleaning by backfiltration due to the lack of a second dialysate port on the FH88 may be a possible explanation. Greater membrane plugging due to higher ultrafiltration rates in HF may be another factor. Patient variability was found to be another factor in dialyzer reuse. The cleaning effectiveness of various dilutions of PAS was also tested in this study. The number of uses achieved was not found to vary significantly with PAS strength; however, a greater frequency of second or third reprocessing was required with more dilute cleaning solution. The authors found the dilution achieved on the Renatron reprocessing machine using the currently marketed PAS concentrate to be the most cost effective.
Disinfection↗